Targeting the mTOR Pathway for the Prevention of ER-Negative Breast Cancer

Abhijit Mazumdar; William M Tahaney; Jamal L Hill; Yun Zhang; Sumankalai Ramachandran; Jitesh Kawedia; Jing Qian; Alejandro Contreras; Michelle I Savage; Lana A Vornik; Shizuko Sei; Altaf Mohammed; Powel H Brown

doi:10.1158/1940-6207.CAPR-22-0106

Targeting the mTOR Pathway for the Prevention of ER-Negative Breast Cancer

Cancer Prev Res (Phila). 2022 Dec 1;15(12):791-802. doi: 10.1158/1940-6207.CAPR-22-0106.

Authors

Affiliations

¹ Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.
² Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.
³ Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
⁴ Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
⁵ Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
⁶ Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland.

Abstract

Our results show that everolimus delays mammary tumor formation in multiple mouse models, suggesting that mTOR inhibitors will be useful for the prevention of ER-negative and triple-negative breast cancer in humans. See related Spotlight, p. 787.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Animals
Breast Neoplasms* / drug therapy
Breast Neoplasms* / metabolism
Breast Neoplasms* / prevention & control
Everolimus / pharmacology
Everolimus / therapeutic use
Female
Humans
Mammary Neoplasms, Animal*
Mice
Receptors, Estrogen / metabolism
TOR Serine-Threonine Kinases

Substances

Receptors, Estrogen
TOR Serine-Threonine Kinases
Everolimus
MTOR protein, human

Grants and funding

P30 CA016672/CA/NCI NIH HHS/United States